2 iv d1+8) for at least 6 cycles every 21 days starting within 6 weeks post-operatively. The randomization was balanced within three strata: 1) FIGO I-IIA, 2) FIGO IIB-IIIC with residual tumor 10mm, 3) FIGO IIB-IIIC with residual tumor > 10 mm or FIGO IV. Primary endpoint is overall survival. Results: We enrolled 1,724 pts and administered 5,271 cycles TC and 5,130 cycles TCG. All baseline characteristics of the patients in both arms were well balanced. Most pts received 6+ cycles (87.2% TC, 86.3% TCG). Previous interim analyses have shown that TCG was tolerable but induced more hematological toxicity and that addition of gemcitabine did not improve overall survival in patients with FIGO stage IIB-IV disease. Approximately 11% of the patients had FIGO stage I-IIA disease. The late breaking abstract will report an analysis with a follow-up until end of January 2009 (median follow-up and range will be reported) including disease free survival and overall survival data in Stage I-IIA patients. Survival data for the two treatment arms will be compared using a log-rank test.
Conclusions:
The final data will show if addition of G to TC provides any relevant benefit for patients with stage I-IIA ovarian cancer.
